7595 Stock Overview
Pharmigene, Inc. designs, develops, manufactures, and sells diagnostic tests in Taiwan and internationally.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 1/6 |
Dividends | 0/6 |
Pharmigene, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | NT$19.80 |
52 Week High | NT$25.70 |
52 Week Low | NT$18.90 |
Beta | 0.14 |
1 Month Change | -2.94% |
3 Month Change | -2.94% |
1 Year Change | -11.61% |
3 Year Change | -21.74% |
5 Year Change | n/a |
Change since IPO | -20.48% |
Recent News & Updates
Recent updates
Shareholder Returns
7595 | TW Biotechs | TW Market | |
---|---|---|---|
7D | -0.5% | 1.0% | 1.5% |
1Y | -11.6% | -21.7% | 26.1% |
Return vs Industry: 7595 exceeded the TW Biotechs industry which returned -21.7% over the past year.
Return vs Market: 7595 underperformed the TW Market which returned 26.1% over the past year.
Price Volatility
7595 volatility | |
---|---|
7595 Average Weekly Movement | 5.1% |
Biotechs Industry Average Movement | 4.3% |
Market Average Movement | 4.2% |
10% most volatile stocks in TW Market | 8.0% |
10% least volatile stocks in TW Market | 1.9% |
Stable Share Price: 7595 has not had significant price volatility in the past 3 months.
Volatility Over Time: 7595's weekly volatility (5%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1994 | n/a | Sophia Zhan | https://pharmigene.com.tw |
Pharmigene, Inc. designs, develops, manufactures, and sells diagnostic tests in Taiwan and internationally. It offers molecular diagnostics to test adverse drug reactions; and DNA extraction products for gene expression analysis, clinical molecular diagnosis, human identity testing, forensics, and biomedical research applications. The company also provides pharmacogenomics test, drug allergy test, and functional medicine test services.
Pharmigene, Inc. Fundamentals Summary
7595 fundamental statistics | |
---|---|
Market cap | NT$999.21m |
Earnings (TTM) | -NT$48.46m |
Revenue (TTM) | NT$132.34m |
7.6x
P/S Ratio-20.6x
P/E RatioIs 7595 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
7595 income statement (TTM) | |
---|---|
Revenue | NT$132.34m |
Cost of Revenue | NT$84.24m |
Gross Profit | NT$48.10m |
Other Expenses | NT$96.56m |
Earnings | -NT$48.46m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.96 |
Gross Margin | 36.34% |
Net Profit Margin | -36.62% |
Debt/Equity Ratio | 169.4% |
How did 7595 perform over the long term?
See historical performance and comparison